Peginterferon lambda-1a
Single 180 µg subcutaneous injection of peginterferon lambda within 7 days ofsymptom onset or first positive swab if asymptomatic.
Placebo
Single 180 µg subcutaneous injection of saline placebo within 7 days ofsymptom onset or first positive swab if asymptomatic.
COVID 19 outpatients
Adult patients between the ages of 18 and 70 years, confirmed COVID-19 infection by PCR within 5 days of symptom onset (fever, respiratory symptoms, sore throat), and discharged to home isolation.
Double-blind.
Multicenter, 6 institutions in Toronto, Canada.
Because of non identical matching placebo, one of two study personnel administering the medication was aware of the treatmentallocation. After administering the medication, all further follow-up (phone calls and study visits) was completed by study personnel unaware of treatment allocation.
Type III Interferon.
TOGETHER interferon lambda, 2022 NCT04727424
peginterferon (n=916) vs. placebo (n=1020)
randomized controlled trial
risk of bias NA
single injection of Peginterferon Lambda 180 mcg
placebo
COVID 19 outpatients
double-blind
Brazil, 12 sites
preliminary results
ACTIV-2 SNG001, 2022 NCT04518410
SNG001 inhaled interferon beta (n=-9) vs. placebo (n=-9)